Bifogade filer
AlzeCure's rights issue oversubscribed according to preliminary results
Martin Jönsson CEO AlzeCure Pharma
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT IN WHOLE OR IN PART TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN ALZECURE. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.
AlzeCure Pharma AB (“AlzeCure” or the “Company”), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced the preliminary outcome of the new share issue with preferential rights for shareholders (the “Rights Issue”) that closed on July 22, 2025. Preliminary figures show that approximately 212 per cent of the Rights Issue was subscribed for and thus oversubscribed.
The subscription period for the Rights Issue expired on July 22, 2025 and preliminary figures show that 19,666,132 shares, corresponding to approximately 89 percent of the entire issue, were subscribed for with the support of subscription rights. In addition, 27,171,095 additional shares were subscribed for without the support of subscription rights, in total for the Rights Issue a subscription level of approximately 212 per cent. No compensation has been given to any participant in the issue. Should the subscription level be confirmed after final calculation by the Board of Directors of the Company, the Board of Directors intend to exercise the option to expand the Rights Issue with the over-allotment option as disclosed in the information material, which would mean that AlzeCure issues 22,073,800 new shares in the Rights Issue and 4,545,455 additional new shares after exercising the over-allotment option, a total of 26,619,255 new shares.
The figures are preliminary and may change after final tally, verification of application forms and decision on allocation. There is no guarantee that the final outcome will correspond to the preliminary outcome but may, on the contrary, be both lower and higher, even significantly. AlzeCure will publish the final outcome as soon as the final tally and allocation have taken place, which is expected to happen within the next few days.
Advisors
AlzeCure has engaged Zonda Partners AB and Synch Advokat AB as financial and legal advisors respectively in connection with the Rights Issue. Corpura Fondkommission AB also acted as joint bookrunner.